Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Earth Science Tech, Inc.’s (ETST) European Industrial Hemp and Mr. Checkout Could be Key Players in 2018

  • ETST projects a breakout year in 2018 from its new line of High Grade Full Spectrum Cannabinoids, marketed as a cannabinoid complex
  • Checkout sells to major retailers, such as Walmart and Target, as well as a network of independent distributors and retail owners
  • ETST’s new line is sourced from European industrial hemp, but it is mixed, bottled and packaged in the U.S.

Earth Science Tech, Inc. (OTC: ETST) is projecting a breakout year in 2018, resetting its executive team and implementing a new marketing strategy. Playing key roles in the predictions of higher volume and performance are new Netherlands-sourced industrial hemp-based products and Mr. Checkout, the specialty distributor that focuses on retail placement (http://ibn.fm/aRPfX).

The company recently launched its revamped and repackaged line of industrial hemp products as a cannabinoid complex. It uses a CO2 extraction process with organically grown and unfiltered industrial hemp. It sources the product from Europe, but it is mixed, bottled and packaged in the U.S. The European Industrial Hemp Association (EIHA) is working with the World Health Organization (WHO) for a product review, and its next meeting is set for May 2018 (http://ibn.fm/Ok2ET).

ETST is an innovative biotech company based in Doral, Florida. Its new line consists of High Grade Full Spectrum Cannabinoids product. It is focused on the cannabinoid, nutraceutical and pharmaceutical fields, and it also conducts R&D for certain medical devices. The new cannabinoid complex line is unique, because it offers the user a specific disclosure of the milligrams (mg) of each cannabinoid. The cannabinoid complex is rich in Terpenes and Saponins, ETST said.

Mr. Checkout, a distributor originally launched in 1989, specializes in distribution to major retailers, such as Walmart, Target and Walgreens, and it also to a network of 1,100 independent distributors and 50,000 independent retail owners within a national network in the U.S. It also offers comprehensive logistics expertise in shipping and boasts a ‘Fast Track’ program designed to get product onto retail shelves quickly (http://ibn.fm/zI8dd).

ETST markets a 100 percent natural and organic high grade hemp cannabidiol and holds three wholly-owned subsidiaries: Earth Science Pharmaceutical has a line of low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioilD is targeted to the recreational market.

For more information, visit the company’s website at www.EarthScienceTech.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Earth Science Tech, Inc. ETST | Leave a comment

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) “Seed to Derivatives” – Vertical Integration in Burgeoning Cannabis Market

  • Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives”
  • Development and commercialization of therapeutic pharmaceuticals and nutraceuticals
  • Patented formulation and delivery technologies

Scientific studies have provided empirical credence to the medical efficacy of cannabinoids for multiple maladies. Globally, researchers and biopharmaceutical companies are now laser focused on cannabinoid-based therapeutics that may hold blockbuster medical potential, providing solutions to a range of unmet medical needs. However, current drug delivery techniques remain antiquated. There are inherent metabolic and bioavailability issues affecting the consistent, effective delivery of cannabinoids. It’s becoming clear that these new pharmaceutical therapeutics require revolutionary delivery techniques. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is establishing new paradigms in cannabinoid drug development and delivery.

Pivot Pharmaceuticals is transforming the development and commercialization of these new therapeutic pharmaceuticals and nutraceuticals with unique drug delivery platform technologies. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals, and it has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical) and Solmic Solubilisation technology (oral) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. The company recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office (http://ibn.fm/6Oi4A), and these latest patent filings join an established number of global rights to topical, oral, transdermal, food and beverage technologies that Pivot has already secured.

Pivot’s pipeline of potential CBD-based pharmaceuticals now covers treatment indications for supportive care to relieve nausea, mucositis and pain, including cancer-related and menstrual pain, dermatological conditions and even glaucoma. Pivot is also developing and commercializing an array of pharmaceutical-grade formulations for cannabinoid-based consumer health care products.

With enhanced drug delivery and development well underway, Pivot has turned to its next business objective, vertical integration. The company just announced a Letter of Intent for the proposed acquisition of Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://ibn.fm/ERNrg). Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility capable of producing a cumulative 10,000 kilograms per year.

Pivot is already a differentiated player in the Canadian cannabis industry due to its unique approach to enhanced dosing and bioavailability of cannabinoids with proven pharmaceutical and patented formulation and delivery systems. With the acquisition of Agro-Biotech, Pivot Pharmaceuticals expects to become vertically integrated, controlling the entire manufacturing process from “seed to derivatives” and capturing margin along the entire supply chain.

In the news release, Dr. Patrick Frankham, Pivot CEO, stated, “I am delighted to welcome Agro-Biotech to Pivot… With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization. Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway. After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives. Pivot will only work with partners who truly control their processes and have the finest infrastructure and qualified personnel. We believe that these characteristics will define best in class products for wellness and health conscious consumers using bio-cannabis….”

This latest announcement follows a pattern of strong corporate development by Pivot Pharmaceuticals and uniquely positons the company to become a major force in the burgeoning cannabis markets not only in Canada but around the world.

For more information, visit the company’s website at www.PivotPharma.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Pivot Pharmaceuticals Inc. PVOTF | Leave a comment

MissionIRNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Enters LOI Detailing Proposed Acquisition of Agro-Biotech Inc.

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) yesterday announced its entry into a non-binding letter of intent pursuant to which it proposes to acquire Agro-Biotech Inc., a Health Canada ACMPR licensed producer located in Saint-Eustache, Quebec. Upon completion of the proposed transaction, which is expected to occur by April 15, 2018, Agro-Biotech will continue to operate on a standalone basis. “With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization. Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway,” Dr. Patrick Frankham, CEO of Pivot, stated in the news release. “After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives.”

To view the full press release, visit http://ibn.fm/VEphJ

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot Pharmaceutical’s subsidiary, Pivot Green Stream Health Solutions Inc., will focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids that can receive a Health Canada Natural Health Product designation. For more information, visit www.PivotPharma.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pivot Pharmaceuticals Inc. PVOTF | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Technology Could Provide Ideal Drug Delivery of Cannabinoids

Pressure BioSciences’ (OTCQB: PBIO) patented technology may provide the ideal transport for CBD and other cannabinoids. The company’s novel Ultra Shear Technology (“UST) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids. An article discussing the company reads: “Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. …Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.”

To view the full article, visit http://ibn.fm/Sb9Xg

About Pressure BioSciences Inc.

Pressure BioSciences Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of PBI’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Joins the Enterprise Ethereum Alliance

Net Element (NASDAQ: NETE), a global technology and value-added solutions group, recently announced that it has joined the Enterprise Ethereum Alliance (“EEA”). The EEA is a network comprised of over 250 innovative companies seeking to augment Ethereum adoption as an enterprise-grade technology, with research and development focused on privacy, confidentiality, scalability and security. Net Element’s entrance into the EEA is complementary to many of the company’s initiatives, including its decentralized blockchain technology solution that will permit endless value-added services. “We are excited to be a part of the Ethereum Alliance, which connects Fortune 500 enterprises, startups, academics and technology vendors with Ethereum subject matter experts,” Net Element CEO Oleg Firer stated in the news release.

To view the full press release, visit http://ibn.fm/MfFQc

About Net Element

Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.NetElement.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Net Element Inc. NETE | Leave a comment

MissionIRNewsBreaks – Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRA: 6F6) (WKN: A2AKL8) Enters Agreement to Acquire Stake in Howyl Ventures Inc.

Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) this morning said that it will acquire 28.5% of all issued and outstanding shares of Howyl Ventures Inc. including its decentralized project marketplace platform, Capaciti, for $1,000,000 CAD, subject to all requisite regulatory approvals. Per the agreement, the total purchase price will be satisfied through cash installments totaling $100,000 and the issuance of 364,372 common shares in the capital of Victory Square to the shareholder(s) of Howyl at a deemed issue price of $2.47 per share. In accordance with the terms of the agreement, the shares shall be subject to resale restrictions, which permit 8% of the shares to be eligible to be free-trading four months from the date of issuance to satisfy the statutory hold period and an additional 8% every three months after. “Howyl’s existing global talent marketplace, combined with deep industry expertise and an exceptionally strong management and technical team, will bring Victory Square into another technology-driven vertical that will experience rapid growth over the next 10 years,” Victory Square CEO Shafin Diamond Tejani stated in the news release.

To view the full press release, visit http://ibn.fm/rMPai

About Victory Square Technologies Inc.

Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.VictorySquare.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Victory Square Technologies Inc. VSQTF | Leave a comment

Pressure BioSciences Inc. (PBIO) Agreement with ISS, Inc. Shows Potential to Enhance Drug Discovery and Development

  • The two companies entered co-marketing and distribution agreement to be implemented worldwide
  • Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
  • The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year

A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://ibn.fm/hRbo0).

Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.

ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.

“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.

The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://ibn.fm/QuG2q).

With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).

Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.

For more information, visit the company’s website at www.PressureBioSciences.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Earth Science Tech, Inc. (ETST) Advances in Prosperous Cannabis Industry

Science-based biotechnology company Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. An article discussing the company reads: “Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.”

To view the full article, visit http://ibn.fm/IuKaG

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, the company’s CBD Oil is 100% natural and organic. Earth Science Tech’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, validates the company’s position as a leading nutritional and dietary supplement brand for High Grade Hemp CBD Oil. For more information, visit the company’s website at www.EarthScienceTech.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Earth Science Tech, Inc. ETST, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Issues Update on California Lithium Exploration

Lithium-focused mining company Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) this morning issued an update on the ongoing exploration program at its California lithium properties. Per the news release, the company and its drilling contractors have completed six exploration boreholes across the Bristol Dry Lake Project area, and three of the exploration holes have had temporary sampling casing installed in order to facilitate the collection of high quality lithium brine samples. Drilling is also underway on an observation well. When completed, this well will allow for robust pumping tests to be performed at the project. Detailed lithium brine analyses are expected to be issued following the collection of representative brine samples and completion of related quality assurance testing. All data gathered from the Bristol Dry Lake Project will be used to advance the maiden resource estimate, which is expected to be released toward the end of Q2 2018. Standard also confirmed plans for a large-scale, detailed gravity geophysical survey of the Cadiz Dry Lake lithium property, which is expected to commence on February 21, 2018.

To view the full press release, visit http://ibn.fm/zdACk

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation. Please visit the Company’s website at http://nnw.fm/standardlithium

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Standard Lithium Ltd. STLHF | Leave a comment

Pressure BioSciences Inc. (PBIO) Just Might Have the Ideal Drug Delivery Technology for Cannabinoids

  • The tide of cannabis legalization continues to rise
  • Medical cannabis market on pace to hit $56 billion in seven years
  • Company’s proprietary technology improves the bioavailability of cannabinoids

With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.

Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.

Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).

Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.

Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.

Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.

Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.

The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.

For more information, visit the company’s website at www.PressureBioSciences.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Pressure BioSciences Inc. PBIO | Leave a comment